- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02870426
Collection and Characterisation of Human Olfactory Ensheathing Cells
We aim to retrieve olfactory bulbs (OBs) from suitable human donors. We have defined two groups who will qualify:
Group 1 - Deceased Donors:
1A: Donors after brainstem death (DBDs) undergoing solid organ donation
1B: Donors after brainstem death (DBDs) considered unsuitable for solid organ donation
Group 2 - Living Donors:
Neurosurgical patients undergoing anterior cranial surgery in which the olfactory nerve (ON) is cut as part of the surgical procedure. The OB of the concomitant severed ON would be donated.
We aim to optimise OB collection and Olfactory Ensheathing Cell (OEC) culture and storage. We will study the effects of patient diagnosis, age, cause of death (if applicable), co-morbidities and warm ischaemic time on cell survival and regenerative function.
In future studies we aim to store OECs in a GMP facility and transplant OECs into patients with spinal cord injuries.
Study Overview
Status
Conditions
Detailed Description
Spinal cord injury (SCI) is a devastating condition. To date there is no treatment to improve outcome. There is limited regenerative capacity of the central nervous system (CNS), such that damaged neurons and severed axons are not replaced.
A substantial body of evidence suggests that olfactory ensheathing cells (OECs) obtained from olfactory bulbs (OBs) facilitate neuronal regeneration in rodents and humans with SCI. Indeed, transplanting autologous OECs from an OB into the injury site improved neurological outcome in a patient with SCI.
Harvesting autologous OBs to culture OECs has several disadvantages:
- If the OECs do not grow in vitro, the transplantation is abandoned;
- The retrieval procedure exposes a paralysed patient to the risks of craniotomy;
- Excising an OB can impair the sense of smell; and
- The number of OECs obtained is limited to one OB.
Investigators will collect human OECs from suitable donors which we have defined as two groups. Group 1 patients will be brain dead donors identified by the neuro-intensive care team as potential candidates for solid organ donation. The OBs will be retrieved as near to death as possible. Group 2 patients will be living donors undergoing elective neurosurgery in which the olfactory nerve is sacrificed as part of that procedure.
There are two OBs located at the anterior skull base, responsible for transmitting the sensation of smell from the nose to the brain. Obtaining OECs requires a craniotomy (opening the skull) to remove the OBs.
PHASE 1 will be divided into 2 stages. In stage 1 we will culture OECs and characterise them in the central laboratory. We aim to determine how the yield of OECs and their regenerative properties are affected by freeze-thaw, time left at room temperature and time left at 40C before culture as well as patient age. Each harvested sample will be transferred to the lab for further processing. Processing includes but is not limited to histological fixation, sectioning and staining, cell culture and storage. Some OECs will be frozen in liquid nitrogen to determine whether they can indeed be stored. In stage 2 we will transfer OECs outside St. George's to a GMP facility (to be determined). In the GMP facility, the OECs will be processed and stored according to the optimised conditions we have determined.
In PHASE 2, the OECs will be transplanted into patients with SCI.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Marios Papadopoulos, FRCS (SN)
- Phone Number: 02087254179
- Email: mpapadop@sgul.ac.uk
Study Contact Backup
- Name: Florence Hogg, MBChB
- Email: fhogg@sgul.ac.uk
Study Locations
-
-
Tooting
-
London, Tooting, United Kingdom, SW17 0QT
- Recruiting
- St George's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion criteria:
Group 1 - Deceased Donors 1A
- Diagnosis of brainstem death, AND
- Consent from next of kin (NoK) for organ donation
- Consent from NoK for removal of olfactory bulbs (OBs)
- Coroner's consent for removal of OBs (when needed).
1B
- Diagnosis of brainstem death, AND
- Contraindications for solid organ donation
- Consent from NoK for removal of OBs
- Coroners consent for removal of OBs (when needed)
Group 2 - Living Donors
- Patients having anterior cranial surgery in which the ON may be cut or removed as part of the procedure.
- Consent from the operating surgeon to remove the OB of the corresponding ON in the event it is cut during the operation
- Consent from the patient for removal of the OB of the corresponding ON in the event it is cut during the operation
Exclusion criteria:
- Children (<18 years old)
- Damage to anterior skull base including OBs
- Meningitis
And applicable to group 2 only:
Patients unable to consent for surgery
Study Plan
How is the study designed?
Design Details
- Observational Models: Other
- Time Perspectives: Other
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Group 1A:
Donors after brainstem death (DBDs) undergoing solid organ donation
|
For Group 1A the craniotomy will occur during organ retrieval for transplantation under aseptic technique.
For Group 1B it would occur as a separate surgical procedure prior to palliation under full asepsis.
|
|
Group 1B:
Donors after brainstem death (DBDs) considered unsuitable for solid organ donation
|
For Group 1A the craniotomy will occur during organ retrieval for transplantation under aseptic technique.
For Group 1B it would occur as a separate surgical procedure prior to palliation under full asepsis.
|
|
Group 2:
Neurosurgical patients undergoing anterior cranial surgery in which the olfactory nerve (ON) is cut as part of the surgical procedure.
The OB of the concomitant severed ON would be donated.
|
Group 2: The patients routine anterior cranial surgery would proceed as planned without change to the surgical procedure.
In the event that the ON had to be sacrificed for the purposes of surgery the OB of the concomitant nerve would be retrieved.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Ability to culture olfactory ensheathing cells from human donors
Time Frame: 10-15 days
|
Number of olfactory ensheathing cells cultured per olfactory bulb at days 10-15 in vitro.
|
10-15 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Effect of cause of death for Group 1 donors
Time Frame: 10-15 days
|
Plot of cause of death vs. Number of olfactory ensheathing cells cultured per olfactory bulb at days 10-15 in vitro.
|
10-15 days
|
|
Effect of patient age
Time Frame: 10-15 days
|
Plot of patient age vs. Number of olfactory ensheathing cells cultured per olfactory bulb at days 10-15 in vitro.
|
10-15 days
|
|
Effect of freeze/thaw cycles
Time Frame: 10-15 days
|
Plot of number of freeze/thaw cycles vs. Number of olfactory ensheathing cells cultured at days 10-15 in vitro.
|
10-15 days
|
|
Effect of storage in liquid nitrogen
Time Frame: up to 1 month
|
Plot of Number of olfactory ensheathing cells cultured at days 10-15 in vitro when cells are cultured fresh vs. after one week and one month storage in liquid nitrogen.
|
up to 1 month
|
|
Effect of time from extraction to culture at room temperature
Time Frame: 1 month
|
Plot of time from extraction to culture vs. Number of olfactory ensheathing cells cultured.
|
1 month
|
|
Effect of time from extraction to culture at 4 deg C
Time Frame: 1 month
|
Plot of time from extraction to culture at 4 deg C vs. Number of olfactory ensheathing cells cultured.
|
1 month
|
Collaborators and Investigators
Investigators
- Principal Investigator: Marios Papadopoulos, FRCS (SN), St George's, University of London
- Principal Investigator: Samira Saadoun, PhD, St George's, University of London
Publications and helpful links
General Publications
- Tabakow P, Jarmundowicz W, Czapiga B, Fortuna W, Miedzybrodzki R, Czyz M, Huber J, Szarek D, Okurowski S, Szewczyk P, Gorski A, Raisman G. Transplantation of autologous olfactory ensheathing cells in complete human spinal cord injury. Cell Transplant. 2013;22(9):1591-612. doi: 10.3727/096368912X663532.
- Miedzybrodzki R, Tabakow P, Fortuna W, Czapiga B, Jarmundowicz W. The olfactory bulb and olfactory mucosa obtained from human cadaver donors as a source of olfactory ensheathing cells. Glia. 2006 Nov 1;54(6):557-65. doi: 10.1002/glia.20395.
- Raisman G. Olfactory ensheathing cells and repair of brain and spinal cord injuries. Cloning Stem Cells. 2004;6(4):364-8. doi: 10.1089/clo.2004.6.364.
- Li Y, Decherchi P, Raisman G. Transplantation of olfactory ensheathing cells into spinal cord lesions restores breathing and climbing. J Neurosci. 2003 Feb 1;23(3):727-31. doi: 10.1523/JNEUROSCI.23-03-00727.2003.
- Keyvan-Fouladi N, Li Y, Raisman G. How do transplanted olfactory ensheathing cells restore function? Brain Res Brain Res Rev. 2002 Oct;40(1-3):325-7. doi: 10.1016/s0165-0173(02)00215-1.
- Raisman G. Olfactory ensheathing cells - another miracle cure for spinal cord injury? Nat Rev Neurosci. 2001 May;2(5):369-75. doi: 10.1038/35072576.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 16.0069
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Study Data/Documents
-
Individual Participant Data Set
Information comments: The project documents will be available directly from the research team. Please e-mail Dr Florence Hogg fhogg@sgul.ac.uk
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Spinal Cord Injury
-
Ecole Polytechnique Fédérale de LausanneRecruitingChronic Spinal Cord Injury | Spinal Cord Injury (SCI) | Spinal Cord Injury | SCI - Spinal Cord Injury | SCI | Subacute Spinal Cord InjurySwitzerland
-
Lian-Cing Yan, MSPTNot yet recruitingSpinal Cord Injury | Spinal Cord Stimulation | Spinal Cord Injury/Damage | Spinal Cord Injury Thoracic | Spinal Cord Stimulation (SCS) | Spinal Cord Injury T1-L2 | Epidural Electrical StimulationTaiwan
-
Xuanwu Hospital, BeijingBeijing Pins Medical Co., Ltd; Beijing Xinzhida Neural Technology Co., Ltd; Hangzhou...RecruitingSpinal Cord Injury | Motor Deficits | Gait Impairment | Gait Training | Spinal Cord Injury Cervical | Spinal Cord Injuries (SCI) | Motor Impairment | Spinal Cord Injury, Chronic | Spinal Cord Injury Thoracic | Spinal Cord Injury (Quadraplegia)China
-
Taipei Veterans General Hospital, TaiwanThe Industrial Technology Research InstituteUnknownSpinal Cord Injuries | Complete Spinal Cord Injury | Incomplete Spinal Cord InjuryTaiwan
-
Chang Gung Memorial HospitalNot yet recruitingSpine Injury | Complete Spinal Cord Injury | Incomplete Spinal Cord Injury | Cord Injury, Spinal | Cord Infarction Spinal
-
University of FloridaEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedSCI - Spinal Cord Injury | Incomplete Spinal Cord InjuryUnited States
-
Jill M. Wecht, Ed.D.Icahn School of Medicine at Mount SinaiRecruitingBlood Pressure | Spinal Cord Injuries | SCI - Spinal Cord Injury | Blood Pressure Disorders | Traumatic Spinal Cord Injury | Acute Spinal Cord Injury | Neuromodulation | Spinal Cord StimulationUnited States
-
MetroHealth Medical CenterNational Institute of Neurological Disorders and Stroke (NINDS); Case Western...RecruitingSpinal Cord Injuries | Spinal Cord Injury at C5-C7 Level | Spinal Cord Injury CervicalUnited States
-
Anne BrydenNational Institute of Neurological Disorders and Stroke (NINDS); Case Western... and other collaboratorsRecruitingSpinal Cord Injuries | Spinal Cord Injury at C5-C7 Level | Spinal Cord Injury Cervical | Spinal Cord Injury at C5-C7 Level With Complete Lesion | Spinal Cord Injury at C5-C7 Level With Incomplete LesionUnited States
-
NervGen PharmaTerminatedSpinal Cord Injuries | Chronic Spinal Cord Injury | Subacute Spinal Cord InjuryUnited States
Clinical Trials on Frontal Craniotomy and retrieval of OBs
-
Al Hayah University In CairoRecruiting
-
Juan M. Ramos AcevedoNot yet recruiting
-
Tiffany HodgesNot yet recruitingGlioma | Malignant Brain TumorsUnited States
-
Tampere University HospitalGE HealthcareWithdrawnAnesthesia, GeneralFinland
-
Tianjin Medical University General HospitalCompleted
-
Jasper GerritsenUniversity Medical Center Groningen; University Hospital, Ghent; Medical Center... and other collaboratorsRecruitingGlioblastoma | Brain Neoplasms | Brain Cancer | Brain Tumor | Glioblastoma Multiforme | Astrocytoma, Grade IV | Glioblastoma Multiforme of BrainNetherlands, Belgium
-
University Hospital, AngersUnknown
-
LactalisCompleted
-
National Cancer Institute (NCI)Completed
-
OPKO Health, Inc.CompletedCOVID-19 | Coronavirus | SARS-CoV2 InfectionUnited States